The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate (Q39706003)

14 September 2017

The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate (English)

1 reference

14 September 2017

1 reference

1

Kenneth A Iczkowski

1 reference

14 September 2017

7

David G Bostwick

1 reference

14 September 2017

Jingxin Qiu

2

1 reference

14 September 2017

Junqi Qian

3

1 reference

14 September 2017

Matthew C Somerville

4

1 reference

14 September 2017

Roger S Rittmaster

5

1 reference

14 September 2017

Gerald L Andriole

6

1 reference

14 September 2017

language of work or name

English

0 references

publication date

1 January 2005

1 reference

14 September 2017

1 reference

14 September 2017

65

1 reference

14 September 2017

1

1 reference

14 September 2017

76-82

1 reference

14 September 2017

Cancer statistics, 2004

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.08.042

The effect of finasteride in men with benign prostatic hyperplasia. 1992.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.08.042

Efficacy of finasteride is maintained in patients with benign prostatic hyperplasia treated for 5 years. The North American Finasteride Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.08.042

Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.08.042

Finasteride. A review of its potential in the treatment of benign prostatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.08.042

Long-term (7 to 8-year) experience with finasteride in men with benign prostatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.08.042

Treatment of benign prostatic hyperplasia with 5-alpha-reductase inhibitor: morphological changes in patients who fail to respond

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.08.042

Can prostate epithelial content predict response to hormonal treatment of patients with benign prostatic hyperplasia?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.08.042

Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? PLESS Study Group. Proscar Long-Term Efficacy and Safety Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.08.042

Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.08.042

Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.08.042

The histology of radiation therapy effect on prostate adenocarcinoma as assessed by needle biopsy after brachytherapy boost. Correlation with biochemical failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.08.042

Gleason score 7 prostate cancer: a heterogeneous entity? Correlation with pathologic parameters and disease-free survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.08.042

Morphological and hormonal changes in the ventral and dorsolateral prostatic lobes of rats treated with finasteride, a 5-alpha reductase inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.08.042

Saw palmetto extract: newest (and oldest) treatment alternative for men with symptomatic benign prostatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.08.042

Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.08.042

Zonal biochemical and morphological characteristics in BPH.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.08.042

Ageing and prostate: age-related changes in androgen receptors of epithelial cells from benign hypertrophic glands compared with cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.08.042

Regional variation of cytosol androgen receptors throughout the diseased human prostate gland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.08.042

Finasteride-induced prostatic involution by apoptosis in dogs with benign prostatic hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.08.042

The influence of finasteride on the development of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.08.042

Does finasteride alter the pathology of the prostate and cancer grading?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.08.042

Assessment of prostate carcinoma in core needle biopsy--definition of minimal criteria for the diagnosis of cancer in biopsy material

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.08.042

10.1016/J.UROLOGY.2004.08.042

7 January 2021

Identifiers

DOI

1 reference

14 September 2017

1 reference